The effects of different familial Alzheimer’s disease mutations on APP processing in vivo

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1758-9193
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
The effects of different familial Alzheimer’s disease mutations on APP processing in vivo ; volume:9 ; number:1 ; day:16 ; month:2 ; year:2017 ; pages:1-10 ; date:12.2017
Alzheimer's research & therapy ; 9, Heft 1 (16.2.2017), 1-10, 12.2017

Schlagwort
Biopharmazie
Pharmakodynamik
Pharmakokinetik

Urheber
Thordardottir, Steinunn
Beteiligte Personen und Organisationen
Kinhult Ståhlbom, Anne
Almkvist, Ove
Thonberg, Håkan
Eriksdotter, Maria
Zetterberg, Henrik
Blennow, Kaj
Graff, Caroline
SpringerLink (Online service)

DOI
10.1186/s13195-017-0234-1
URN
urn:nbn:de:1111-2017031011380
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:49 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Thordardottir, Steinunn
  • Kinhult Ståhlbom, Anne
  • Almkvist, Ove
  • Thonberg, Håkan
  • Eriksdotter, Maria
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Graff, Caroline
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Fluid biomarkers in Alzheimer’s disease – current concepts

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease

BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease

Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study

Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Differential effects of familial Alzheimer’s disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity

Differential effects of familial Alzheimer’s disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity

Verbundene Objekte